AGMB-101 / AgomAb Therapeutics - LARVOL DELTA

Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis-Focused Pipeline (Businesswire) - "The proceeds from the Series D will be used to further advance the ongoing clinical development of Agomab’s lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFβ1R), in patients with fibrostenosing Crohn’s disease (FSCD). Interim data from the Phase 2a STENOVA trial are expected in the first quarter of 2025. In addition, proceeds will be used to advance the clinical development for AGMB-447…as well as initial clinical development of AGMB-101…"

Financing • P2a data • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease